Related Experiment Videos
The emergence of resistance to targeted cancer therapeutics
Ingo K Mellinghoff1, Charles L Sawyers
1Departments of Medicine and Molecular Biology Institute, UCLA School of Medicine, Los Angeles, CA 90095, USA.
Abstract:
Drug resistance has always been a concern in cancer treatment, often blamed on the genetic complexity and instability of tumor cells. While studies of cancer cell lines have implicated an array of potential mechanisms, it has been difficult to translate these insights into clinically meaningful improvements in cancer treatment. The successful deployment of molecularly targeted therapeutics in some cancers has led to widespread optimism that this approach will become broadly applicable. Despite their early promise in the clinic, the novel therapeutics are often plagued with the age old problem of acquired drug resistance. Progress in understanding why certain patients respond and why some develop resistance can be made rapidly through studies of the drug target in tumor tissue from patient. One important lesson is that many cancers, even in the most advanced stages, continue to rely on a limited number of critical oncogenic signals for maintenance of the malignant phenotype. This article reviews the mechanisms of drug resistance to a variety of cancer therapeutics and provides an approach for how measures of drug target activity can be incorporated into clinical trial design.
Insights
Acquired drug resistance in cancer treatment remains a challenge. Studying drug targets in patient tumor tissue offers insights into resistance mechanisms and clinical trial design for targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Drug resistance is a major obstacle in cancer treatment, often attributed to tumor cell genetic complexity.
- Despite advances in molecularly targeted therapies, acquired drug resistance remains a significant clinical problem.
- Translating findings from cancer cell lines to clinical practice has proven difficult.
Purpose of the Study:
- To review mechanisms of drug resistance to various cancer therapeutics.
- To propose an approach for incorporating drug target activity measures into clinical trial design.
- To highlight the importance of studying drug targets in patient tumor tissue.
Main Methods:
- Review of existing literature on cancer drug resistance mechanisms.
- Analysis of the role of oncogenic signals in cancer maintenance.
- Discussion of strategies for integrating target activity assessment into clinical trials.
Main Results:
- Many advanced cancers depend on a limited set of critical oncogenic signals.
- Studying drug targets in patient tumor tissue can accelerate understanding of treatment response and resistance.
- Molecularly targeted therapeutics face the persistent challenge of acquired resistance.
Conclusions:
- Understanding drug resistance requires direct study of drug targets within patient tumors.
- Incorporating measures of drug target activity into clinical trials is crucial for optimizing targeted cancer therapy.
- Despite challenges, targeted therapies hold promise when resistance mechanisms are addressed.